Webinar Video | Life Sciences Session #4: How to optimise your regulatory exclusivity rights for pharmaceutical products?
In the fourth online Life Sciences Session our experts, Kirian Claeyé and Laura Traest, will be focusing on regulatory exclusivity rights for pharmaceutical products, which will include data exclusivity, orphan exclusivity, SPCs and paediatric rewards. They will navigate the maze of regulatory exclusivity rights, update you on a number of significant recent developments, and discuss what is still to come. Specific topics will include:
- The SPC manufacturing waiver
- The CJEU’s latest case-law on SPC rights: Santen and Royalty Pharma
- The European Commission’s review of Orphan Exclusivity and Paediatric Extensions
- The General Court’s very recent Polpharma ruling on Data Exclusivity
Written by
Recommended articles
Are parallel importers necessarily allowed to rebox medicines in case of visible traces from ATDs? The CJEU says NO
Pharmaceutical companies are obliged to affix an anti-tampering device (‘ATD’) on prescription-only medicines to enable verification of whether a medicine’s packaging has been tampered with. Parallel importers argue that this results in an overarching objective necessity to ‘rebox’ such medicines.
Read on
Can parallel importers (re)brand generic medicines? The CJEU limits the ‘room for manoeuvre’
If a branded medicine and its generic version are put on the EEA market by economically-linked undertakings, is a parallel importer then allowed to rebrand and repackage the imported generic version as the branded reference medicine? After the Brussels Court of Appeal had referred questions on this issue for a preliminary ruling two years ago, the CJEU has now clarified the limits.
Read on
New rules on medical force majeure and the medical certificate
A new Act, which includes various provisions on incapacity for work, was published in the Belgian State Gazette on 18 November 2022.
Read on